High-flow nasal oxygen may cost less than NIV in patients with acute respiratory failure, but not in patients critically ill with COVID-19.

The global respiratory care devices market is projected to grow from USD 23.6 billion in 2025 to USD 33.6 billion by 2030, ...

Hard-to-get insurance, high costs, and limited treatment access are key barriers to care for COPD patients in the U.S., a new ...

COPD can damage the lungs' defences, making pneumonia more severe. Doctors explain symptoms, treatment, and prevention tips ...

Evidence tells us that a treatable traits intervention will improve quality of life for people with chronic obstructive ...

A new national survey released by the COPD Action Alliance reveals that patients who are diagnosed with COPD (Chronic Obstructive Pulmonary Disease) face serious challenges accessing treatment due to ...

Prioritizing communications between patients and health care providers and increasing patient education about chronic ...

AstraZeneca is conducting a study titled Chronicling the COPD Patient Journey and Change in Impact of a Single Inhaler Combination Therapy on COPD Symptoms, Quality of Life and Exacerbations Following ...

The recent clinical study update from Regeneron Pharmaceuticals and Sanofi focuses on the investigation of Itepekimab, an anti-IL-33 monoclonal antibody, to understand its effects ...

Prioritizing communications between patients and health care providers and increasing patient education about chronic obstructive pulmonary disease (COPD) could help improve patient care, according to ...